Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.
Howard M. Sandler, MD, of Cedars-Sinai Medical Center discusses the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).
John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).
John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
